AU2001235365A1 - Method for correlating blood coagulation activity with markers in body fluids, e.g. urine - Google Patents

Method for correlating blood coagulation activity with markers in body fluids, e.g. urine

Info

Publication number: AU2001235365A1
Authority: AU; Australia
Prior art keywords: marker; blood coagulation; coagulation activity; species; amount
Prior art date: 2000-02-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2001235365A

Other languages

English (en)

Inventor

Lars C. Borris

Michael Rud Lassen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Besst Test ApS

Original Assignee

ACTIWATCH APS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-23

Filing date

2001-02-23

Publication date

2001-09-03

2001-02-23 Application filed by ACTIWATCH APS filed Critical ACTIWATCH APS

2001-09-03 Publication of AU2001235365A1 publication Critical patent/AU2001235365A1/en

Status Abandoned legal-status Critical Current

Links

230000023555 blood coagulation Effects 0.000 title claims description 356
230000000694 effects Effects 0.000 title claims description 312
238000000034 method Methods 0.000 title claims description 255
210000001124 body fluid Anatomy 0.000 title claims description 168
239000010839 body fluid Substances 0.000 title claims description 168
210000002700 urine Anatomy 0.000 title claims description 95
239000003550 marker Substances 0.000 claims description 394
238000012360 testing method Methods 0.000 claims description 118
238000009739 binding Methods 0.000 claims description 88
230000027455 binding Effects 0.000 claims description 86
239000012634 fragment Substances 0.000 claims description 86
230000008685 targeting Effects 0.000 claims description 83
108010094028 Prothrombin Proteins 0.000 claims description 78
102100027378 Prothrombin Human genes 0.000 claims description 76
229940039716 prothrombin Drugs 0.000 claims description 76
210000004369 blood Anatomy 0.000 claims description 64
239000008280 blood Substances 0.000 claims description 64
108010041201 prothrombin fragment 1 Proteins 0.000 claims description 60
238000001514 detection method Methods 0.000 claims description 57
102000004190 Enzymes Human genes 0.000 claims description 47
108090000790 Enzymes Proteins 0.000 claims description 47
229940088598 enzyme Drugs 0.000 claims description 47
108090000765 processed proteins & peptides Proteins 0.000 claims description 46
102000004196 processed proteins & peptides Human genes 0.000 claims description 44
108090000190 Thrombin Proteins 0.000 claims description 37
239000007787 solid Substances 0.000 claims description 37
229960004072 thrombin Drugs 0.000 claims description 36
238000012544 monitoring process Methods 0.000 claims description 34
108010041206 prothrombin fragment 2 Proteins 0.000 claims description 29
JWICNZAGYSIBAR-LEEGLKINSA-N (4s)-4-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-5-[[2-[[(2s)-3-carboxy-1-[[(2s)-1-[[1-[[(2s)-1-[[(2s)-4-carboxy-1-[[2-[[2-[[2-[[(2s)-1-[[(1s)-1-carboxy-4-(diaminomethylideneamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)C(CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)N)CC1=CC=CC=C1 JWICNZAGYSIBAR-LEEGLKINSA-N 0.000 claims description 28
101800000974 Fibrinopeptide A Proteins 0.000 claims description 28
102400000525 Fibrinopeptide A Human genes 0.000 claims description 28
239000000463 material Substances 0.000 claims description 24
125000000539 amino acid group Chemical group 0.000 claims description 23
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 22
108010049003 Fibrinogen Proteins 0.000 claims description 21
102000008946 Fibrinogen Human genes 0.000 claims description 21
229940012952 fibrinogen Drugs 0.000 claims description 21
108010073385 Fibrin Proteins 0.000 claims description 20
102000009123 Fibrin Human genes 0.000 claims description 20
229950003499 fibrin Drugs 0.000 claims description 19
239000012530 fluid Substances 0.000 claims description 16
239000002245 particle Substances 0.000 claims description 16
229920001184 polypeptide Polymers 0.000 claims description 14
239000000020 Nitrocellulose Substances 0.000 claims description 13
229920001220 nitrocellulos Polymers 0.000 claims description 13
229920001282 polysaccharide Polymers 0.000 claims description 13
239000005017 polysaccharide Substances 0.000 claims description 13
230000008859 change Effects 0.000 claims description 11
150000001413 amino acids Chemical class 0.000 claims description 10
239000007788 liquid Substances 0.000 claims description 9
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical group [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 9
102000003992 Peroxidases Human genes 0.000 claims description 7
108010072035 antithrombin III-protease complex Proteins 0.000 claims description 7
238000012217 deletion Methods 0.000 claims description 6
230000037430 deletion Effects 0.000 claims description 6
239000000208 fibrin degradation product Substances 0.000 claims description 6
238000003780 insertion Methods 0.000 claims description 6
230000037431 insertion Effects 0.000 claims description 6
238000006467 substitution reaction Methods 0.000 claims description 6
238000011144 upstream manufacturing Methods 0.000 claims description 6
239000003154 D dimer Substances 0.000 claims description 5
238000000576 coating method Methods 0.000 claims description 5
108010052295 fibrin fragment D Proteins 0.000 claims description 5
239000000282 fibrinogen degradation product Substances 0.000 claims description 5
230000009870 specific binding Effects 0.000 claims description 5
239000011248 coating agent Substances 0.000 claims description 4
BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 claims description 4
108040007629 peroxidase activity proteins Proteins 0.000 claims description 4
239000013641 positive control Substances 0.000 claims description 4
238000011002 quantification Methods 0.000 claims description 4
239000008279 sol Substances 0.000 claims description 4
230000003100 immobilizing effect Effects 0.000 claims description 3
230000003993 interaction Effects 0.000 claims description 3
239000004816 latex Substances 0.000 claims description 3
229920000126 latex Polymers 0.000 claims description 3
229940012957 plasmin Drugs 0.000 claims description 3
238000001035 drying Methods 0.000 claims description 2
230000005012 migration Effects 0.000 claims description 2
238000013508 migration Methods 0.000 claims description 2
238000012546 transfer Methods 0.000 claims description 2
150000004676 glycans Chemical class 0.000 claims 2
241000894007 species Species 0.000 description 270
239000000523 sample Substances 0.000 description 257
238000006243 chemical reaction Methods 0.000 description 70
238000003556 assay Methods 0.000 description 61
210000002381 plasma Anatomy 0.000 description 45
206010053567 Coagulopathies Diseases 0.000 description 29
239000007790 solid phase Substances 0.000 description 28
230000015271 coagulation Effects 0.000 description 27
238000005345 coagulation Methods 0.000 description 27
230000035602 clotting Effects 0.000 description 26
238000001356 surgical procedure Methods 0.000 description 25
239000003153 chemical reaction reagent Substances 0.000 description 20
239000000427 antigen Substances 0.000 description 18
102000036639 antigens Human genes 0.000 description 18
108091007433 antigens Proteins 0.000 description 18
239000012491 analyte Substances 0.000 description 17
238000004458 analytical method Methods 0.000 description 17
239000003146 anticoagulant agent Substances 0.000 description 17
239000000975 dye Substances 0.000 description 17
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical group OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 16
229960005348 antithrombin iii Drugs 0.000 description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
102000004411 Antithrombin III Human genes 0.000 description 15
108090000935 Antithrombin III Proteins 0.000 description 15
229940127219 anticoagulant drug Drugs 0.000 description 15
238000011282 treatment Methods 0.000 description 15
230000004913 activation Effects 0.000 description 14
AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 14
230000015572 biosynthetic process Effects 0.000 description 13
-1 europium ion Chemical class 0.000 description 13
108090000623 proteins and genes Proteins 0.000 description 13
102000015081 Blood Coagulation Factors Human genes 0.000 description 12
108010039209 Blood Coagulation Factors Proteins 0.000 description 12
208000007536 Thrombosis Diseases 0.000 description 12
239000003114 blood coagulation factor Substances 0.000 description 12
229960002897 heparin Drugs 0.000 description 12
229920000669 heparin Polymers 0.000 description 12
230000000984 immunochemical effect Effects 0.000 description 12
235000018102 proteins Nutrition 0.000 description 12
102000004169 proteins and genes Human genes 0.000 description 12
239000000126 substance Substances 0.000 description 12
101800004937 Protein C Proteins 0.000 description 11
102000017975 Protein C Human genes 0.000 description 11
238000005259 measurement Methods 0.000 description 11
150000004804 polysaccharides Chemical class 0.000 description 11
239000000758 substrate Substances 0.000 description 11
101800001700 Saposin-D Proteins 0.000 description 10
239000010931 gold Substances 0.000 description 10
229940039715 human prothrombin Drugs 0.000 description 10
229960000856 protein c Drugs 0.000 description 10
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
108010000499 Thromboplastin Proteins 0.000 description 9
102000002262 Thromboplastin Human genes 0.000 description 9
238000010168 coupling process Methods 0.000 description 9
201000010099 disease Diseases 0.000 description 9
229910052737 gold Inorganic materials 0.000 description 9
229920000642 polymer Polymers 0.000 description 9
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 8
241001465754 Metazoa Species 0.000 description 8
239000000306 component Substances 0.000 description 8
230000008878 coupling Effects 0.000 description 8
238000005859 coupling reaction Methods 0.000 description 8
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
238000002372 labelling Methods 0.000 description 8
239000012071 phase Substances 0.000 description 8
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 8
241001494479 Pecora Species 0.000 description 7
235000001014 amino acid Nutrition 0.000 description 7
230000000890 antigenic effect Effects 0.000 description 7
208000015294 blood coagulation disease Diseases 0.000 description 7
230000009852 coagulant defect Effects 0.000 description 7
208000035475 disorder Diseases 0.000 description 7
239000003814 drug Substances 0.000 description 7
229910001385 heavy metal Inorganic materials 0.000 description 7
238000003018 immunoassay Methods 0.000 description 7
239000012528 membrane Substances 0.000 description 7
239000000203 mixture Substances 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
229920002307 Dextran Polymers 0.000 description 6
102000001690 Factor VIII Human genes 0.000 description 6
108091005804 Peptidases Proteins 0.000 description 6
125000003275 alpha amino acid group Chemical group 0.000 description 6
230000010100 anticoagulation Effects 0.000 description 6
229960000301 factor viii Drugs 0.000 description 6
230000036961 partial effect Effects 0.000 description 6
150000003904 phospholipids Chemical class 0.000 description 6
230000036470 plasma concentration Effects 0.000 description 6
230000002285 radioactive effect Effects 0.000 description 6
238000002965 ELISA Methods 0.000 description 5
108010054218 Factor VIII Proteins 0.000 description 5
108010074860 Factor Xa Proteins 0.000 description 5
208000032843 Hemorrhage Diseases 0.000 description 5
239000004365 Protease Substances 0.000 description 5
230000002159 abnormal effect Effects 0.000 description 5
239000012190 activator Substances 0.000 description 5
210000001772 blood platelet Anatomy 0.000 description 5
239000011575 calcium Substances 0.000 description 5
230000000295 complement effect Effects 0.000 description 5
230000007812 deficiency Effects 0.000 description 5
238000003745 diagnosis Methods 0.000 description 5
239000003527 fibrinolytic agent Substances 0.000 description 5
230000003480 fibrinolytic effect Effects 0.000 description 5
238000011534 incubation Methods 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
230000006623 intrinsic pathway Effects 0.000 description 5
238000012125 lateral flow test Methods 0.000 description 5
230000002980 postoperative effect Effects 0.000 description 5
238000012216 screening Methods 0.000 description 5
230000000007 visual effect Effects 0.000 description 5
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
102100023804 Coagulation factor VII Human genes 0.000 description 4
108010014172 Factor V Proteins 0.000 description 4
108010023321 Factor VII Proteins 0.000 description 4
108010066124 Protein S Proteins 0.000 description 4
102000029301 Protein S Human genes 0.000 description 4
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
230000005856 abnormality Effects 0.000 description 4
230000001133 acceleration Effects 0.000 description 4
230000000740 bleeding effect Effects 0.000 description 4
229910052791 calcium Inorganic materials 0.000 description 4
239000007795 chemical reaction product Substances 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
230000000875 corresponding effect Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
206010012601 diabetes mellitus Diseases 0.000 description 4
238000002405 diagnostic procedure Methods 0.000 description 4
230000006624 extrinsic pathway Effects 0.000 description 4
229940012413 factor vii Drugs 0.000 description 4
230000006870 function Effects 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
230000008105 immune reaction Effects 0.000 description 4
208000014674 injury Diseases 0.000 description 4
210000003127 knee Anatomy 0.000 description 4
229910052747 lanthanoid Inorganic materials 0.000 description 4
150000002602 lanthanoids Chemical class 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
230000000269 nucleophilic effect Effects 0.000 description 4
239000000047 product Substances 0.000 description 4
238000000159 protein binding assay Methods 0.000 description 4
239000000700 radioactive tracer Substances 0.000 description 4
230000035945 sensitivity Effects 0.000 description 4
239000000377 silicon dioxide Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
238000001179 sorption measurement Methods 0.000 description 4
102000002260 Alkaline Phosphatase Human genes 0.000 description 3
108020004774 Alkaline Phosphatase Proteins 0.000 description 3
102000010911 Enzyme Precursors Human genes 0.000 description 3
108010062466 Enzyme Precursors Proteins 0.000 description 3
229910052693 Europium Inorganic materials 0.000 description 3
108010048049 Factor IXa Proteins 0.000 description 3
108010014173 Factor X Proteins 0.000 description 3
108010001336 Horseradish Peroxidase Proteins 0.000 description 3
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
239000004793 Polystyrene Substances 0.000 description 3
229940096437 Protein S Drugs 0.000 description 3
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
208000001435 Thromboembolism Diseases 0.000 description 3
108010046334 Urease Proteins 0.000 description 3
206010047249 Venous thrombosis Diseases 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
238000009825 accumulation Methods 0.000 description 3
230000003213 activating effect Effects 0.000 description 3
230000002776 aggregation Effects 0.000 description 3
238000004220 aggregation Methods 0.000 description 3
229960002685 biotin Drugs 0.000 description 3
235000020958 biotin Nutrition 0.000 description 3
239000011616 biotin Substances 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
230000002860 competitive effect Effects 0.000 description 3
238000011109 contamination Methods 0.000 description 3
230000002596 correlated effect Effects 0.000 description 3
230000002950 deficient Effects 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
208000009190 disseminated intravascular coagulation Diseases 0.000 description 3
230000005670 electromagnetic radiation Effects 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
230000029142 excretion Effects 0.000 description 3
239000007850 fluorescent dye Substances 0.000 description 3
125000000524 functional group Chemical group 0.000 description 3
239000011521 glass Substances 0.000 description 3
235000019420 glucose oxidase Nutrition 0.000 description 3
230000002439 hemostatic effect Effects 0.000 description 3
239000005556 hormone Substances 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
230000036046 immunoreaction Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000003446 ligand Substances 0.000 description 3
125000005647 linker group Chemical group 0.000 description 3
239000002502 liposome Substances 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000011236 particulate material Substances 0.000 description 3
230000037361 pathway Effects 0.000 description 3
229920002223 polystyrene Polymers 0.000 description 3
230000008569 process Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
238000005070 sampling Methods 0.000 description 3
229910052709 silver Inorganic materials 0.000 description 3
238000003860 storage Methods 0.000 description 3
125000003396 thiol group Chemical group [H]S* 0.000 description 3
238000011179 visual inspection Methods 0.000 description 3
238000005406 washing Methods 0.000 description 3
MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 2
OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 description 2
KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
102000016938 Catalase Human genes 0.000 description 2
108010053835 Catalase Proteins 0.000 description 2
102100022641 Coagulation factor IX Human genes 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
238000008157 ELISA kit Methods 0.000 description 2
206010014522 Embolism venous Diseases 0.000 description 2
108010076282 Factor IX Proteins 0.000 description 2
108010080865 Factor XII Proteins 0.000 description 2
102000000429 Factor XII Human genes 0.000 description 2
108010015133 Galactose oxidase Proteins 0.000 description 2
108010015776 Glucose oxidase Proteins 0.000 description 2
102000053187 Glucuronidase Human genes 0.000 description 2
108010060309 Glucuronidase Proteins 0.000 description 2
229920002527 Glycogen Polymers 0.000 description 2
101000651439 Homo sapiens Prothrombin Proteins 0.000 description 2
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
102000004316 Oxidoreductases Human genes 0.000 description 2
108090000854 Oxidoreductases Proteins 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
108010090804 Streptavidin Proteins 0.000 description 2
108010079274 Thrombomodulin Proteins 0.000 description 2
239000002250 absorbent Substances 0.000 description 2
230000002745 absorbent Effects 0.000 description 2
229960001138 acetylsalicylic acid Drugs 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
230000003321 amplification Effects 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
102000005936 beta-Galactosidase Human genes 0.000 description 2
108010005774 beta-Galactosidase Proteins 0.000 description 2
102000006995 beta-Glucosidase Human genes 0.000 description 2
108010047754 beta-Glucosidase Proteins 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
229960000074 biopharmaceutical Drugs 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
238000007675 cardiac surgery Methods 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
238000004891 communication Methods 0.000 description 2
230000021615 conjugation Effects 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
ZQMIGQNCOMNODD-UHFFFAOYSA-N diacetyl peroxide Chemical compound CC(=O)OOC(C)=O ZQMIGQNCOMNODD-UHFFFAOYSA-N 0.000 description 2
238000007598 dipping method Methods 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
229960004222 factor ix Drugs 0.000 description 2
108010073651 fibrinmonomer Proteins 0.000 description 2
230000020764 fibrinolysis Effects 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
229930182830 galactose Natural products 0.000 description 2
108010046301 glucose peroxidase Proteins 0.000 description 2
229940096919 glycogen Drugs 0.000 description 2
230000036541 health Effects 0.000 description 2
230000023597 hemostasis Effects 0.000 description 2
239000002628 heparin derivative Substances 0.000 description 2
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
238000013150 knee replacement Methods 0.000 description 2
208000019423 liver disease Diseases 0.000 description 2
239000003094 microcapsule Substances 0.000 description 2
230000027939 micturition Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
150000002772 monosaccharides Chemical group 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
150000002482 oligosaccharides Polymers 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000005855 radiation Effects 0.000 description 2
230000035484 reaction time Effects 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
210000003296 saliva Anatomy 0.000 description 2
239000010703 silicon Substances 0.000 description 2
229910052710 silicon Inorganic materials 0.000 description 2
239000004332 silver Substances 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
201000005665 thrombophilia Diseases 0.000 description 2
238000011541 total hip replacement Methods 0.000 description 2
230000008733 trauma Effects 0.000 description 2
208000004043 venous thromboembolism Diseases 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
238000001262 western blot Methods 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
SYJPAKDNFZLSMV-HYXAFXHYSA-N (Z)-2-methylpropanal oxime Chemical compound CC(C)\C=N/O SYJPAKDNFZLSMV-HYXAFXHYSA-N 0.000 description 1
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
UUORGSXWPOMXJJ-UHFFFAOYSA-N 1-[azido(ethyl)phosphoryl]ethane Chemical compound CCP(=O)(CC)N=[N+]=[N-] UUORGSXWPOMXJJ-UHFFFAOYSA-N 0.000 description 1
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
HQNSWBRZIOYGAW-UHFFFAOYSA-N 2-chloro-n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC(Cl)=C1 HQNSWBRZIOYGAW-UHFFFAOYSA-N 0.000 description 1
QFYSZYAVKZUZCM-UHFFFAOYSA-N 2-diazonio-1,1,1-trifluorohex-2-en-3-olate Chemical compound CCCC(=O)C(=[N+]=[N-])C(F)(F)F QFYSZYAVKZUZCM-UHFFFAOYSA-N 0.000 description 1
JBVSBLLOZVDAAZ-UHFFFAOYSA-N 2-diazonio-1-[(2-methylpropan-2-yl)oxy]ethenolate Chemical compound CC(C)(C)OC([O-])=C[N+]#N JBVSBLLOZVDAAZ-UHFFFAOYSA-N 0.000 description 1
UWBALSPTLHOGFE-UHFFFAOYSA-N 2-diazonio-1-phenoxyethenolate Chemical compound [N-]=[N+]=CC(=O)OC1=CC=CC=C1 UWBALSPTLHOGFE-UHFFFAOYSA-N 0.000 description 1
ZSTBZBURMWJKSQ-UHFFFAOYSA-N 2-diazonio-1-phenylethenolate Chemical compound N#[N+]C=C([O-])C1=CC=CC=C1 ZSTBZBURMWJKSQ-UHFFFAOYSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
NNMALANKTSRILL-LXENMSTPSA-N 3-[(2z,5e)-2-[[3-(2-carboxyethyl)-5-[(z)-[(3e,4r)-3-ethylidene-4-methyl-5-oxopyrrolidin-2-ylidene]methyl]-4-methyl-1h-pyrrol-2-yl]methylidene]-5-[(4-ethyl-3-methyl-5-oxopyrrol-2-yl)methylidene]-4-methylpyrrol-3-yl]propanoic acid Chemical compound O=C1C(CC)=C(C)C(\C=C\2C(=C(CCC(O)=O)C(=C/C3=C(C(C)=C(\C=C/4\C(\[C@@H](C)C(=O)N\4)=C\C)N3)CCC(O)=O)/N/2)C)=N1 NNMALANKTSRILL-LXENMSTPSA-N 0.000 description 1
IXEVBKYJNFWMPR-UHFFFAOYSA-N 3-phenyl-3-(trifluoromethyl)diazirine Chemical compound C=1C=CC=CC=1C1(C(F)(F)F)N=N1 IXEVBKYJNFWMPR-UHFFFAOYSA-N 0.000 description 1
VCTBSHQJICJJFV-UHFFFAOYSA-N 4-azido-1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(N=[N+]=[N-])=CC=C1F VCTBSHQJICJJFV-UHFFFAOYSA-N 0.000 description 1
RTUYNYSPUHQITK-UHFFFAOYSA-N 4-methylbenzoyl azide Chemical compound CC1=CC=C(C(=O)N=[N+]=[N-])C=C1 RTUYNYSPUHQITK-UHFFFAOYSA-N 0.000 description 1
GZAJOEGTZDUSKS-UHFFFAOYSA-N 5-aminofluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(N)=CC=C21 GZAJOEGTZDUSKS-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
FWEOQOXTVHGIFQ-UHFFFAOYSA-N 8-anilinonaphthalene-1-sulfonic acid Chemical compound C=12C(S(=O)(=O)O)=CC=CC2=CC=CC=1NC1=CC=CC=C1 FWEOQOXTVHGIFQ-UHFFFAOYSA-N 0.000 description 1
GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
229920000178 Acrylic resin Polymers 0.000 description 1
239000004925 Acrylic resin Substances 0.000 description 1
101800001401 Activation peptide Proteins 0.000 description 1
102400000069 Activation peptide Human genes 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
229920000945 Amylopectin Polymers 0.000 description 1
229920000856 Amylose Polymers 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
206010002388 Angina unstable Diseases 0.000 description 1
201000005657 Antithrombin III deficiency Diseases 0.000 description 1
200000000007 Arterial disease Diseases 0.000 description 1
206010003178 Arterial thrombosis Diseases 0.000 description 1
206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
208000020446 Cardiac disease Diseases 0.000 description 1
206010008132 Cerebral thrombosis Diseases 0.000 description 1
229910052684 Cerium Inorganic materials 0.000 description 1
229920002101 Chitin Polymers 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
102100026735 Coagulation factor VIII Human genes 0.000 description 1
206010011091 Coronary artery thrombosis Diseases 0.000 description 1
229920002558 Curdlan Polymers 0.000 description 1
239000001879 Curdlan Substances 0.000 description 1
206010051055 Deep vein thrombosis Diseases 0.000 description 1
229920004943 Delrin® Polymers 0.000 description 1
AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
229920002079 Ellagic acid Polymers 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
108010061932 Factor VIIIa Proteins 0.000 description 1
108010074105 Factor Va Proteins 0.000 description 1
108010074864 Factor XI Proteins 0.000 description 1
102000008857 Ferritin Human genes 0.000 description 1
238000008416 Ferritin Methods 0.000 description 1
108050000784 Ferritin Proteins 0.000 description 1
229910052688 Gadolinium Inorganic materials 0.000 description 1
102000002464 Galactosidases Human genes 0.000 description 1
108010093031 Galactosidases Proteins 0.000 description 1
206010064571 Gene mutation Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004366 Glucose oxidase Substances 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
206010051124 Hyperfibrinogenaemia Diseases 0.000 description 1
206010051125 Hypofibrinogenaemia Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
201000001429 Intracranial Thrombosis Diseases 0.000 description 1
108010093008 Kinins Proteins 0.000 description 1
102000002397 Kinins Human genes 0.000 description 1
229920001543 Laminarin Polymers 0.000 description 1
239000005717 Laminarin Substances 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
229920000057 Mannan Polymers 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
208000004221 Multiple Trauma Diseases 0.000 description 1
MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical group ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
BXEFQPCKQSTMKA-UHFFFAOYSA-N OC(=O)C=[N+]=[N-] Chemical class OC(=O)C=[N+]=[N-] BXEFQPCKQSTMKA-UHFFFAOYSA-N 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241000906034 Orthops Species 0.000 description 1
108010013639 Peptidoglycan Proteins 0.000 description 1
108700020962 Peroxidase Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
108010053210 Phycocyanin Proteins 0.000 description 1
108010004729 Phycoerythrin Proteins 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
201000005660 Protein C Deficiency Diseases 0.000 description 1
101710111620 Protein C activator Proteins 0.000 description 1
206010051292 Protein S Deficiency Diseases 0.000 description 1
229910052772 Samarium Inorganic materials 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
229940122388 Thrombin inhibitor Drugs 0.000 description 1
102100026966 Thrombomodulin Human genes 0.000 description 1
101710120037 Toxin CcdB Proteins 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
239000002253 acid Substances 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
206010000891 acute myocardial infarction Diseases 0.000 description 1
239000008272 agar Substances 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
125000003172 aldehyde group Chemical group 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
238000001949 anaesthesia Methods 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000002429 anti-coagulating effect Effects 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
239000004019 antithrombin Substances 0.000 description 1
208000028922 artery disease Diseases 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
VCJIGSOOIYBSFA-UHFFFAOYSA-N azido formate Chemical class [N-]=[N+]=NOC=O VCJIGSOOIYBSFA-UHFFFAOYSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
239000012965 benzophenone Substances 0.000 description 1
PJHUABJTDFXYRQ-UHFFFAOYSA-N benzoyl azide Chemical compound [N-]=[N+]=NC(=O)C1=CC=CC=C1 PJHUABJTDFXYRQ-UHFFFAOYSA-N 0.000 description 1
235000019400 benzoyl peroxide Nutrition 0.000 description 1
229950011260 betanaphthol Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000008436 biogenesis Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
229910052797 bismuth Inorganic materials 0.000 description 1
JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
229940019700 blood coagulation factors Drugs 0.000 description 1
239000012503 blood component Substances 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
230000002612 cardiopulmonary effect Effects 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000010523 cascade reaction Methods 0.000 description 1
238000001444 catalytic combustion detection Methods 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
239000013522 chelant Substances 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
238000009535 clinical urine test Methods 0.000 description 1
230000001112 coagulating effect Effects 0.000 description 1
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
238000012505 colouration Methods 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
238000004624 confocal microscopy Methods 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
208000026758 coronary atherosclerosis Diseases 0.000 description 1
208000002528 coronary thrombosis Diseases 0.000 description 1
150000001893 coumarin derivatives Chemical class 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
229920006037 cross link polymer Polymers 0.000 description 1
235000019316 curdlan Nutrition 0.000 description 1
229940078035 curdlan Drugs 0.000 description 1
FYLJKQFMQFOLSZ-UHFFFAOYSA-N cyclohexylperoxycyclohexane Chemical compound C1CCCCC1OOC1CCCCC1 FYLJKQFMQFOLSZ-UHFFFAOYSA-N 0.000 description 1
230000000093 cytochemical effect Effects 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 1
239000012933 diacyl peroxide Substances 0.000 description 1
150000004845 diazirines Chemical class 0.000 description 1
150000008049 diazo compounds Chemical class 0.000 description 1
ZWJPCOALBPMBIC-UHFFFAOYSA-N diphenylketene Chemical compound C=1C=CC=CC=1C(=C=O)C1=CC=CC=C1 ZWJPCOALBPMBIC-UHFFFAOYSA-N 0.000 description 1
MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
229960002852 ellagic acid Drugs 0.000 description 1
235000004132 ellagic acid Nutrition 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
229960000610 enoxaparin Drugs 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
125000003700 epoxy group Chemical group 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 1
KIMFKMFUVZLIOO-UHFFFAOYSA-N ethyl benzenecarboperoxoate Chemical compound CCOOC(=O)C1=CC=CC=C1 KIMFKMFUVZLIOO-UHFFFAOYSA-N 0.000 description 1
HZAHPOBLARATTK-UHFFFAOYSA-N ethyl n-diazocarbamate Chemical compound CCOC(=O)N=[N+]=[N-] HZAHPOBLARATTK-UHFFFAOYSA-N 0.000 description 1
OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000002360 explosive Substances 0.000 description 1
108010091897 factor V Leiden Proteins 0.000 description 1
201000007386 factor VII deficiency Diseases 0.000 description 1
238000001506 fluorescence spectroscopy Methods 0.000 description 1
229910052733 gallium Inorganic materials 0.000 description 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
231100000089 gene mutation induction Toxicity 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229940116332 glucose oxidase Drugs 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
125000000291 glutamic acid group Chemical class N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
210000003709 heart valve Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
208000033666 hereditary antithrombin deficiency Diseases 0.000 description 1
208000013746 hereditary thrombophilia due to congenital protein C deficiency Diseases 0.000 description 1
238000011540 hip replacement Methods 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
235000013828 hydroxypropyl starch Nutrition 0.000 description 1
NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000001746 injection moulding Methods 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
150000002561 ketenes Chemical class 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
238000009533 lab test Methods 0.000 description 1
238000003475 lamination Methods 0.000 description 1
229910052746 lanthanum Inorganic materials 0.000 description 1
239000002523 lectin Substances 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000031700 light absorption Effects 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000004807 localization Effects 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
229910052748 manganese Inorganic materials 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
239000002991 molded plastic Substances 0.000 description 1
239000000178 monomer Substances 0.000 description 1
UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
235000007708 morin Nutrition 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
229920001206 natural gum Polymers 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000010606 normalization Methods 0.000 description 1
QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
230000009210 ongoing activation Effects 0.000 description 1
229940127216 oral anticoagulant drug Drugs 0.000 description 1
229940127234 oral contraceptive Drugs 0.000 description 1
239000003539 oral contraceptive agent Substances 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N ornithyl group Chemical group N[C@@H](CCCN)C(=O)O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229960003330 pentetic acid Drugs 0.000 description 1
108010091748 peptide A Proteins 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
239000012466 permeate Substances 0.000 description 1
125000000864 peroxy group Chemical group O(O*)* 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
UFJCUIGMJOFBRX-UHFFFAOYSA-N phenyl n-diazocarbamate Chemical compound [N-]=[N+]=NC(=O)OC1=CC=CC=C1 UFJCUIGMJOFBRX-UHFFFAOYSA-N 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
CPGRMGOILBSUQC-UHFFFAOYSA-N phosphoryl azide Chemical class [N-]=[N+]=NP(=O)(N=[N+]=[N-])N=[N+]=[N-] CPGRMGOILBSUQC-UHFFFAOYSA-N 0.000 description 1
230000002186 photoactivation Effects 0.000 description 1
238000000554 physical therapy Methods 0.000 description 1
238000007842 plasma-based assay Methods 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003223 poly(pyromellitimide-1,4-diphenyl ether) Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920002704 polyhistidine Polymers 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
201000011461 pre-eclampsia Diseases 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003805 procoagulant Substances 0.000 description 1
230000000135 prohibitive effect Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
238000005086 pumping Methods 0.000 description 1
238000012205 qualitative assay Methods 0.000 description 1
238000012207 quantitative assay Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000020964 regulation of blood coagulation Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 1
125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000002764 solid phase assay Methods 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000002594 sorbent Substances 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
229940014800 succinic anhydride Drugs 0.000 description 1
125000001174 sulfone group Chemical group 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
HSVFKFNNMLUVEY-UHFFFAOYSA-N sulfuryl diazide Chemical class [N-]=[N+]=NS(=O)(=O)N=[N+]=[N-] HSVFKFNNMLUVEY-UHFFFAOYSA-N 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
229910052713 technetium Inorganic materials 0.000 description 1
GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
238000010998 test method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
239000003869 thrombin derivative Substances 0.000 description 1
239000003868 thrombin inhibitor Substances 0.000 description 1
238000012337 thromboprophylaxis Methods 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000007704 wet chemistry method Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
229920001221 xylan Polymers 0.000 description 1
150000004823 xylans Chemical class 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1
VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/224—Haemostasis or coagulation

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Biochemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Physics & Mathematics (AREA)
Cell Biology (AREA)
Pathology (AREA)
Food Science & Technology (AREA)
Zoology (AREA)
Biophysics (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Neurosurgery (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Investigating Or Analysing Biological Materials (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Apparatus Associated With Microorganisms And Enzymes (AREA)

AU2001235365A 2000-02-23 2001-02-23 Method for correlating blood coagulation activity with markers in body fluids, e.g. urine Abandoned AU2001235365A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
DKPA200000283		2000-02-23
DKPA200000283		2000-02-23
US21139000P	2000-06-14	2000-06-14
US60211390		2000-06-14
PCT/DK2001/000130 WO2001063299A1 (fr)	2000-02-23	2001-02-23	Methode de correlation de l"activite de coagulation sanguine avec des marqueurs dans des liquides biologiques, par exemple l"urine

Publications (1)

Publication Number	Publication Date
AU2001235365A1 true AU2001235365A1 (en)	2001-09-03

Family

ID=42196641

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2001235365A Abandoned AU2001235365A1 (en)	2000-02-23	2001-02-23	Method for correlating blood coagulation activity with markers in body fluids, e.g. urine

Country Status (7)

Country	Link
US (2)	US20020132370A1 (fr)
EP (1)	EP1281089A1 (fr)
JP (1)	JP2003524187A (fr)
AU (1)	AU2001235365A1 (fr)
CA (1)	CA2437298A1 (fr)
NZ (1)	NZ521534A (fr)
WO (1)	WO2001063299A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7640083B2 (en)	2002-11-22	2009-12-29	Monroe David A	Record and playback system for aircraft
US6902904B2 (en) *	2001-08-27	2005-06-07	Pharmanetics Incorporated	Coagulation assay reagents containing lanthanides
US20030119203A1 (en)	2001-12-24	2003-06-26	Kimberly-Clark Worldwide, Inc.	Lateral flow assay devices and methods for conducting assays
US7285424B2 (en)	2002-08-27	2007-10-23	Kimberly-Clark Worldwide, Inc.	Membrane-based assay devices
US7314763B2 (en)	2002-08-27	2008-01-01	Kimberly-Clark Worldwide, Inc.	Fluidics-based assay devices
US7432105B2 (en)	2002-08-27	2008-10-07	Kimberly-Clark Worldwide, Inc.	Self-calibration system for a magnetic binding assay
US7247500B2 (en)	2002-12-19	2007-07-24	Kimberly-Clark Worldwide, Inc.	Reduction of the hook effect in membrane-based assay devices
US20040197819A1 (en)	2003-04-03	2004-10-07	Kimberly-Clark Worldwide, Inc.	Assay devices that utilize hollow particles
US7851209B2 (en)	2003-04-03	2010-12-14	Kimberly-Clark Worldwide, Inc.	Reduction of the hook effect in assay devices
AU2004286284B2 (en)	2003-10-29	2011-08-25	Mec Dynamics Corp.	Micro mechanical methods and systems for performing assays
ATE497163T1 (de)	2003-11-14	2011-02-15	Alere Switzerland Gmbh	Flüssigprobenanalysevorrichtung mit verschliessbarem probenaufbewahrungsreservoir
US7713748B2 (en)	2003-11-21	2010-05-11	Kimberly-Clark Worldwide, Inc.	Method of reducing the sensitivity of assay devices
US7943395B2 (en)	2003-11-21	2011-05-17	Kimberly-Clark Worldwide, Inc.	Extension of the dynamic detection range of assay devices
US20050112703A1 (en) *	2003-11-21	2005-05-26	Kimberly-Clark Worldwide, Inc.	Membrane-based lateral flow assay devices that utilize phosphorescent detection
US7943089B2 (en)	2003-12-19	2011-05-17	Kimberly-Clark Worldwide, Inc.	Laminated assay devices
US7906276B2 (en)	2004-06-30	2011-03-15	Kimberly-Clark Worldwide, Inc.	Enzymatic detection techniques
US7094528B2 (en)	2004-06-30	2006-08-22	Kimberly-Clark Worldwide, Inc.	Magnetic enzyme detection techniques
US7521226B2 (en)	2004-06-30	2009-04-21	Kimberly-Clark Worldwide, Inc.	One-step enzymatic and amine detection technique
US7148067B2 (en) *	2004-08-31	2006-12-12	The Board Of Trustees Of The University Of Illinois	Thromboplastin reagents
FR2875910B1 (fr) *	2004-09-28	2007-04-06	Vedalab Sa	Dispositifs de diagnostic immunochromatographiques pour la detection d'un analyte dans un echantillon liquide comprenant un temoin positif independant de l'analyte detecte
CN101151533A (zh) *	2005-02-16	2008-03-26	伊利诺斯大学理事会	基于金属螯合脂质的促凝血剂
EP1869082B1 (fr) *	2005-03-04	2011-04-13	The Board Of Trustees Of The University Of Illinois	Modulateur de coagulation et de cascades fibrinolytiques
AU2006319681B2 (en)	2005-11-30	2012-12-13	Abbott Rapid Diagnostics International Unlimited Company	Devices and Methods for Detecting Analytes in Fluid Samples
EP2029768B1 (fr) *	2006-06-06	2013-02-13	Thrombinoscope B.V.	Procédé permettant de déterminer l'activité de la thrombine dans plasma
CA2658795A1 (fr)	2006-07-26	2008-02-07	Abon Biopharm (Hangzhou) Co., Ltd.	Dispositif d'analyse d'un echantillon biologique
WO2008019448A1 (fr) *	2006-08-18	2008-02-21	Macquarie University	Cytomètre en flux fluorescent à déclenchement périodique
US8865454B2 (en) *	2007-03-22	2014-10-21	Scandinavian Micro Biodevices Aps	Flow through system, flow through device and a method of performing a test
WO2009046194A2 (fr)	2007-10-05	2009-04-09	The Board Of Trustees Of The University Of Illinois	Produit d'étanchéité de fibrine
US20100297257A1 (en)	2007-11-09	2010-11-25	National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs)	Anticoagulant antagonist and hemophillia procoagulant
JP4676539B2 (ja) *	2009-02-25	2011-04-27	古河電気工業株式会社	ラテラルフロー型蛍光イムノクロマト法用の標的物質を定量的に検出する装置及びその方法
WO2011049431A1 (fr) *	2009-10-19	2011-04-28	Stichting Katholieke Universiteit, Radboud Universiteit Nijmegen	Mesure du statut de coagulation sanguine dans la salive
WO2011159820A1 (fr) *	2010-06-15	2011-12-22	Bayer Healthcare Llc	Dispositif
US8900822B2 (en) *	2011-11-21	2014-12-02	Ethicon, Inc.	Fibrinogen assay
CN104813166B (zh) *	2012-09-28	2016-05-04	积水医疗株式会社	用于测量非稀释类型免疫层析法试剂中的样品的添加剂
JP6117552B2 (ja) *	2012-12-28	2017-04-19	株式会社Kri	生活習慣病判定支援装置および生活習慣病判定支援システム
US11181534B2 (en)	2014-04-04	2021-11-23	Bloodworks	Routine laboratory and point-of-care (POC) testing for hemostasis
US11143659B2 (en)	2015-01-27	2021-10-12	Arterez, Inc.	Biomarkers of vascular disease
TWI809247B (zh) *	2019-02-08	2023-07-21	日商日本電氣股份有限公司	人類t細胞白血病病毒1型（htlv-1）相關疾病的診斷方法
CN110895283A (zh) *	2019-12-10	2020-03-20	宁波奥丞生物科技有限公司	一种高灵敏度的d-二聚体检测试剂盒及其使用方法
CN113252852B (zh) *	2021-06-04	2021-10-22	金科环境股份有限公司	絮凝剂性能评价与检验设备及方法
CN115201134B (zh) *	2022-09-15	2022-12-27	吉林大学第一医院	一种抗白皮杉醇干扰的肌酐检测试剂盒及其应用
AT527882A1 (de) *	2023-12-19	2025-07-15	Univ Wien Tech	Testvorrichtung und verfahren zur bestimmung von hämatokrit und/oder fibrinogen in einer blutprobe

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5622871A (en) *	1987-04-27	1997-04-22	Unilever Patent Holdings B.V.	Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents
US4642285A (en) *	1975-09-29	1987-02-10	Diamedix Corporation	Sandwich EIA for antigen
EP0146654A3 (fr) *	1980-06-20	1986-08-20	Unilever Plc	Procédé et dispositif pour la réalisation d'essais à liaison spécifique
US4517288A (en) *	1981-01-23	1985-05-14	American Hospital Supply Corp.	Solid phase system for ligand assay
IL63855A (en) *	1981-09-16	1984-10-31	Teva Pharma	Method and kit for detecting pregnancy
US4450239A (en) *	1981-09-23	1984-05-22	Northwestern University	Method of determining pregnanediol in female urine and test device for use therein
US4463090A (en) *	1981-09-30	1984-07-31	Harris Curtis C	Cascade amplification enzyme immunoassay
US4446232A (en) *	1981-10-13	1984-05-01	Liotta Lance A	Enzyme immunoassay with two-zoned device having bound antigens
US4477576A (en) *	1982-07-26	1984-10-16	Mex Research Associates	Antigen assay method and kit
US4496654A (en) *	1983-04-08	1985-01-29	Quidel	Detection of HCG with solid phase support having avidin coating
US4703017C1 (en) *	1984-02-14	2001-12-04	Becton Dickinson Co	Solid phase assay with visual readout
US4647544A (en) *	1984-06-25	1987-03-03	Nicoli David F	Immunoassay using optical interference detection
DE3516579A1 (de) *	1984-11-19	1986-05-22	Boehringer Mannheim Gmbh, 6800 Mannheim	Gerinnungstest auf teststreifen
US4712562A (en) *	1985-01-08	1987-12-15	Jacques J. Ohayon	Outpatient monitoring systems
US4803156A (en) *	1985-09-11	1989-02-07	New York Blood Center	Peptide-beta-lactamase conjugates for enzyme-linked immunoassays
US4845026A (en) *	1985-12-03	1989-07-04	T Cell Sciences, Inc.	Assay systems for detecting cell-free T cell antigen receptor related molecules and the clinical utilities of the assays
US4960692A (en) *	1986-03-18	1990-10-02	Fisher Scientific Company	Assay employing binding pair members on particles and on a filter or membrane
GB8608157D0 (en) *	1986-04-03	1986-05-08	Unilever Plc	Ovulation test chart
US4960691A (en) *	1986-09-29	1990-10-02	Abbott Laboratories	Chromatographic test strip for determining ligands or receptors
US5036000A (en) *	1986-12-16	1991-07-30	Enzymatics, Inc.	Threshold color control system
GB8701432D0 (en) *	1987-01-22	1987-02-25	Unilever Plc	Assays
ATE195022T1 (de) *	1987-04-27	2000-08-15	Unilever Nv	Spezifische bindungstestverfahren
US4943522A (en) *	1987-06-01	1990-07-24	Quidel	Lateral flow, non-bibulous membrane assay protocols
US5447837A (en) *	1987-08-05	1995-09-05	Calypte, Inc.	Multi-immunoassay diagnostic system for antigens or antibodies or both
DE3727610A1 (de) *	1987-08-19	1989-03-02	Behringwerke Ag	Synthetische peptide, gegen diese gerichtete antikoerper und deren verwendung
US4952517A (en) *	1988-02-08	1990-08-28	Hygeia Sciences, Inc.	Positive step immunoassay
AU2684488A (en) *	1988-06-27	1990-01-04	Carter-Wallace, Inc.	Test device and method for colored particle immunoassay
US4975842A (en) *	1988-08-11	1990-12-04	Schering Corporation	Electronic patient diary and patient monitoring process
IT1227293B (it) *	1988-10-06	1991-04-05	Boehringer Biochemia Srl	Dispositivo e metodo per la diagnosi di gravidanza
US5939272A (en) *	1989-01-10	1999-08-17	Biosite Diagnostics Incorporated	Non-competitive threshold ligand-receptor assays
IE903930A1 (en) *	1989-11-06	1991-05-08	Akzo Nv	Immunoassays for and monoclonal antibodies to prothrombin¹activation peptides and their degradation products
US5169786A (en) *	1989-12-19	1992-12-08	Ortho Diagnostic Systems, Inc.	Method of determining levels of extrinsic and intrinsic clotting factors and protein c
ATE140034T1 (de) *	1990-04-17	1996-07-15	Analytical Control Syst Inc	Koagulationsassays und reagenzien
US5217903A (en) *	1990-05-15	1993-06-08	Trustees Of Boston University	Measuring connective tissue breakdown products in body fluids
CA2070813C (fr) *	1990-11-05	1996-10-29	Hendrik Coenraad Hemker	Une methode permettant de determiner la concentration d'anticoagulants
EP0566695B1 (fr) *	1991-01-11	1999-06-02	Quidel Corporation	Methode de dosage en une seule phase a flux lateral et support non- spongieux utilise dedans
US5686315A (en) *	1991-06-14	1997-11-11	Quidel Corporation	Assay device for one step detection of analyte
DK130991D0 (da) *	1991-07-04	1991-07-04	Immunodex K S	Polymere konjugater
US5716795A (en) *	1991-10-04	1998-02-10	Matschiner; John T.	Thrombomodulin-based coagulometric assay of the protein C system
DE4133946A1 (de) *	1991-10-14	1993-04-15	Behringwerke Ag	Funktioneller test und reagenz zur bestimmung von fibrinogen
JP2601075B2 (ja) *	1991-10-21	1997-04-16	株式会社日立製作所	試験片を用いる分析方法および分析装置
SE470274B (sv) *	1991-11-13	1993-12-20	Bjoern Dahlbaeck	Användning av en in vitro-metod för diagnos av blodkoagulationssjukdomar
US5437278A (en) *	1992-01-10	1995-08-01	Wilk; Peter J.	Medical diagnosis system and method
US5666953A (en) *	1993-01-10	1997-09-16	Wilk; Peter J.	System and associated method for providing information for use in forming medical diagnosis
US5506114A (en) *	1992-02-07	1996-04-09	Osborn Laboratories	Methods and kits for detecting the presence or concentration of biological analytes
US5355889A (en) *	1992-06-09	1994-10-18	Albert Eisenstein Health Care Foundation	Monitoring system for producing patient status indicator
US5399500A (en) *	1992-06-26	1995-03-21	Becton Dickinson And Company	Two step process for coating of antibodies to a solid phase
WO1994009371A1 (fr) *	1992-10-09	1994-04-28	Massachusetts Institute Of Technology	Test diagnostique ante mortem pour la detection de la maladie d'alzheimer
US5832448A (en) *	1996-10-16	1998-11-03	Health Hero Network	Multiple patient monitoring system for proactive health management
US5590648A (en) *	1992-11-30	1997-01-07	Tremont Medical	Personal health care system
US5770376A (en) *	1992-12-02	1998-06-23	Biomedical Sciences Research Laboratories, Inc.	Method of diagnosing and treating myocardial infarction and hypertension
US5357427A (en) *	1993-03-15	1994-10-18	Digital Equipment Corporation	Remote monitoring of high-risk patients using artificial intelligence
JP3213832B2 (ja) *	1993-08-06	2001-10-02	日本臓器製薬株式会社	被検物質の活性測定法
FI940823A0 (fi) *	1994-02-22	1994-02-22	Orion Yhtymae Oy	Analysatorkyvett foer turbidimetriska och nefelometriska bestaemningar av helblodsprov
US5738102A (en) *	1994-03-31	1998-04-14	Lemelson; Jerome H.	Patient monitoring system
US5473536A (en) *	1994-04-04	1995-12-05	Spacelabs Medical, Inc.	Method and system for customizing the display of patient physiological parameters on a medical monitor
US5724983A (en) *	1994-08-01	1998-03-10	New England Center Hospitals, Inc.	Continuous monitoring using a predictive instrument
US5521102A (en) *	1994-08-08	1996-05-28	Quidel Corporation	Controlled sensitivity immunochromatographic assay
DE4427785A1 (de) *	1994-08-08	1996-02-15	Behringwerke Ag	Verfahren zum Nachweis von Störungen des Protein C/Protein S-Systems
US5553609A (en) *	1995-02-09	1996-09-10	Visiting Nurse Service, Inc.	Intelligent remote visual monitoring system for home health care service
US5778882A (en) *	1995-02-24	1998-07-14	Brigham And Women's Hospital	Health monitoring system
US5705330A (en) *	1995-04-14	1998-01-06	Abbott Laboratories	Chemiluminescent immunoassay for antibody detection
US5712172A (en) *	1995-05-18	1998-01-27	Wyntek Diagnostics, Inc.	One step immunochromatographic device and method of use
US5739041A (en) *	1995-05-02	1998-04-14	Carter Wallace, Inc.	Diagnostic detection device
US5981298A (en) *	1995-12-13	1999-11-09	Surmodics, Inc.	Immunoassay device and method
US5962215A (en) *	1996-04-05	1999-10-05	Mercury Diagnostics, Inc.	Methods for testing the concentration of an analyte in a body fluid
US5710005A (en) *	1996-10-29	1998-01-20	Biocode, Inc.	Analyte detection with a gradient lateral flow device
US6150115A (en) *	1997-04-04	2000-11-21	Seikagaku Kogyo Kabushiki Kaisha	Quantitative determination method for heparan sulfate and diagnostic method using the same
US5977299A (en) *	1997-04-07	1999-11-02	Dade Behring Marburg Gmbh	Activated peptides and conjugates
US5985675A (en) *	1997-12-31	1999-11-16	Charm Sciences, Inc.	Test device for detection of an analyte
US5876952A (en) *	1997-12-08	1999-03-02	Shieh; Paul	Non-invasive glucose biosensor: determination of glucose in urine
US5985582A (en) *	1997-12-09	1999-11-16	Sigma-Aldrich Co.	Thrombin-based assay for antithrombin III
US6394952B1 (en) *	1998-02-03	2002-05-28	Adeza Biomedical Corporation	Point of care diagnostic systems
WO1999060409A1 (fr) *	1998-05-18	1999-11-25	Link Enterprises Corporation	Fibrinopeptides salivaires utilises comme indicateurs de la coagulabilite sanguine
US6309888B1 (en) *	1998-09-04	2001-10-30	Leuven Research & Development Vzw	Detection and determination of the stages of coronary artery disease
US6444425B1 (en) *	1999-04-02	2002-09-03	Corixa Corporation	Compounds for therapy and diagnosis of lung cancer and methods for their use

2001
- 2001-02-23 EP EP01907396A patent/EP1281089A1/fr not_active Ceased
- 2001-02-23 CA CA002437298A patent/CA2437298A1/fr not_active Abandoned
- 2001-02-23 WO PCT/DK2001/000130 patent/WO2001063299A1/fr not_active Ceased
- 2001-02-23 AU AU2001235365A patent/AU2001235365A1/en not_active Abandoned
- 2001-02-23 US US09/791,384 patent/US20020132370A1/en not_active Abandoned
- 2001-02-23 NZ NZ521534A patent/NZ521534A/en not_active IP Right Cessation
- 2001-02-23 JP JP2001562212A patent/JP2003524187A/ja active Pending
2010
- 2010-01-25 US US12/693,129 patent/US20100129841A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NZ521534A (en)	2004-10-29
WO2001063299A1 (fr)	2001-08-30
US20020132370A1 (en)	2002-09-19
US20100129841A1 (en)	2010-05-27
EP1281089A1 (fr)	2003-02-05
JP2003524187A (ja)	2003-08-12
CA2437298A1 (fr)	2001-08-30

Publication	Publication Date	Title
US20100129841A1 (en)	2010-05-27	Detection of a blood coagulation activity marker in a body fluid sample
US6027904A (en)	2000-02-22	Platelet count assay using thrombospondin or β-thromboglobulin
EP0070300A1 (fr)	1983-01-26	Systeme en phase solide pour essai avec agent de liaison.
US11506674B2 (en)	2022-11-22	Monoclonal antibody against D-dimer and diagnosis agent for detecting D-dimer, crosslinked fibrin and its derivatives containing D-dimer by using the antibody
US20150168407A1 (en)	2015-06-18	Enzyme detection device
FI95752B (fi)	1995-11-30	Määrityskitti ja -menetelmä kokonaisten solujen immunologiseen määritykseen
WO2012025637A1 (fr)	2012-03-01	Procédé et dispositif de dosage d'agglutination
CN102656457A (zh)	2012-09-05	用于诊断前列腺癌的试剂盒和方法
CN116298264A (zh)	2023-06-23	一种用于tm、tat和pic联合检测的试剂卡及其应用
WO2002079782A1 (fr)	2002-10-10	Reactif et procede pour l'immunoanalyse de l'elastase 1, et procede de detection de pathologie pancreatique
WO1998010285A1 (fr)	1998-03-12	Essai de cytometrie de flux pour determiner la thrombocytopenie induite par l'heparine
US5434054A (en)	1995-07-18	Devices for determining hydrolase activity through its hydrolytic release of an immobilized indicator enzyme
US20020187518A1 (en)	2002-12-12	Methods and devices for detecting non-complexed prostate specific antigen
CA1208550A (fr)	1986-07-29	Methode de dosage quantitatif par aggregation avec un enzyme
EP0170345A2 (fr)	1986-02-05	Cytométrie à écoulement
JPH0580053A (ja)	1993-03-30	ヒト子宮体癌細胞の免疫化学的検出方法
US5587291A (en)	1996-12-24	Method for the determination of plasmin α2 -antiplasmin complexes and the use of this method as a mean of determining changes in the fibrinolytic system
WO2006123789A1 (fr)	2006-11-23	Procede d’analyse d’une enzyme
AU2006202646A1 (en)	2006-07-13	Method for correlating blood coagulation activity with markers in body fluids, eg. urine
US6287785B1 (en)	2001-09-11	Homogenous enzyme immunoassay process
EP0756173A1 (fr)	1997-01-29	Reactif de detection de substances et procede de diagnostic de la polyarthrite rhumatoide
WO2008068554A1 (fr)	2008-06-12	Essai d'analyte basé sur le complément
US12429488B2 (en)	2025-09-30	Monoclonal antibody against D-dimer and diagnosis agent for detecting D-dimer, crosslinked fibrin and its derivatives containing D-dimer by using the antibody
EP1054258A1 (fr)	2000-11-22	Méthode homogène de dosage immunologique enzymatique faisant intervenir un second anticorps contre le premier anticorps
JPH0324458A (ja)	1991-02-01	尿中赤血球の免疫学的測定法